参考文献:
1. Cree BAC, HauserSL. Multiple Sclerosis. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, LongoDL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 20e. New York,NY: McGraw-Hill Education; 2018.
2. Browne P,Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A growingglobal problem with widespread inequity. Neurology. 2014;83(11):1022-1024.
3. Lublin FD,Reingold SC, Cohen JA, et al. Defining the clinical course of multiplesclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286.
4. Global,regional, and national burden of multiple sclerosis 1990-2016: a systematicanalysis for the Global Burden of Disease Study 2016. Lancet neurology.2019;18(3):269285.
5. Kamm CP, Uitdehaag BM, Polman CH. Multiplesclerosis: current knowledge and future outlook. European neurology.2014;72(3-4):132-141.
6. Confavreux C,Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain : ajournal of neurology. 2006;129(Pt 3):606-616.
7. Wallin MT, CulpepperWJ, Campbell JD, et al. The prevalence of MS in the United States: Apopulation-based estimate using health claims data. Neurology.2019;92(10):e1029e1040.
8. Cree BAC, Hollenbach JA, Bove R, et al.Silent progression in disease activity-free relapsing multiple sclerosis.Annals of neurology. 2019;85(5):653-666.
9. Kappos L,Butzkueven H, Wiendl H, et al. Greater sensitivity to multiple sclerosisdisability worsening and progression events using a roving versus a fixedreference value in a prospective cohort study. Multiple sclerosis (Houndmills,Basingstoke, England). 2018;24(7):963-973.
10. Filippi M, Rocca MA, Ciccarelli O, et al.MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensusguidelines. Lancet neurology. 2016;15(3):292-303.
11. Galetta SL,Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsingmultiple sclerosis: a systematic review. Arch Intern Med.2002;162(19):21612169.
12. Steinman L,Zamvil SS. How to successfully apply animal studies in experimental allergicencephalomyelitis to research on multiple sclerosis. Annals of neurology.2006;60(1):1221.
13. Martin R.Immunological aspects of experimental allergic encephalomyelitis and multiplesclerosis and their application for new therapeutic strategies. J Neural TransmSuppl. 1997;49:53-67.
14. van Oosten BW,Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonalanti-CD4 antibody cM-T412: results of a randomized, double-blind,placebocontrolled, MR-monitored phase II trial. Neurology. 1997;49(2):351-357.
15. Weinshenker BG,Bass B, Karlik S, Ebers GC, Rice GP. An open trial of OKT3 in patients withmultiple sclerosis. Neurology. 1991;41(7):1047-1052.
16. Massacesi L,Genain CP, Lee-Parritz D, Letvin NL, Canfield D, Hauser SL. Active andpassively induced experimental autoimmune encephalomyelitis in commonmarmosets: a new model for multiple sclerosis. Annals of neurology.1995;37(4):519-530.
17. Hauser SL. TheCharcot Lecture | beating MS: a story of B cells, with twists and turns.Multiple sclerosis (Houndmills, Basingstoke, England). 2015;21(1):8-21.
18. Hauser SL,Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in RelapsingMultiple Sclerosis. The New England journal of medicine. 2017;376(3):221-234.
19. Hauser SL,Waubant E, Arnold DL, et al. B-cell depletion with rituximab inrelapsingremitting multiple sclerosis. The New England journal of medicine.2008;358(7):676-688.
20. Kappos L, Wolinsky JS, Giovannoni G, etal. Progression Independent of Relapse Activity in Patients With TypicalRelapsing Multiple Sclerosis: Pooled Analysis of 2 Randomized Clinical Trials.JAMA neurology. 2020 [In Press].
21. Montalban X,Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary ProgressiveMultiple Sclerosis. The New England journal of medicine. 2017;376(3):209220.
22. Greenfield AL, Hauser SL. B-cell Therapyfor Multiple Sclerosis: Entering an era. Annals of neurology. 2018;83(1):13-26.
23. Sorensen PS, Blinkenberg M. The potentialrole for ocrelizumab in the treatment of multiple sclerosis: current evidenceand future prospects. Therapeutic advances in neurological disorders.2016;9(1):44-52.
24. Li R, PattersonKR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Natureimmunology. 2018;19(7):696-707.
25. Sabatino JJ,Jr., Probstel AK, Zamvil SS. B cells in autoimmune and neurodegenerativecentral nervous system diseases. Nature reviews Neuroscience.2019;20(12):728-745.
26. Hauser SL, Kappos L, Montalban X, et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients withrelapsing and primary progressive multiple sclerosis. European journal ofneurology : the official journal of the European Federation of NeurologicalSocieties. 2019;26(Supplement 1):239.
27. Hauser SL, Bar-Or A, Cohen JA, et al.Ofatumumab versus Teriflunomide in Multiple Sclerosis. The New England journalof medicine. 2020 [in press].
28. Yednock TA,Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention ofexperimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1integrin. Nature. 1992;356(6364):63-66.
29. Rudick RA,Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a forrelapsing multiple sclerosis. The New England journal of medicine.2006;354(9):911-923.
30. Polman CH,O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial ofnatalizumab for relapsing multiple sclerosis. The New England journal ofmedicine. 2006;354(9):899-910.
31. Myhr K-M, Schüler S, Alstadhaug KB, et al.Long-term, real-world effectiveness of natalizumab treatment inrelapsing-remitting multiple sclerosis (RRMS): Data from ≥6 years in the TYSABRI® ObservationalProgram (TOP) Nordic and global cohorts. European journal of neurology : theofficial journal of the European Federation of Neurological Societies.2019;26(Supplement 1):680.
32. Ho PR, KoendgenH, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumabassociatedprogressive multifocal leukoencephalopathy in patients with multiple sclerosis:a retrospective analysis of data from four clinical studies. Lancet neurology.2017;16(11):925-933.
33. Ryerson LZ,Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MSis reduced with extended interval dosing. Neurology. 2019;93(15):e1452-e1462.
34. Calabresi PA,Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients withrelapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind,randomised, placebo-controlled, phase 3 trial. Lancet neurology.2014;13(6):545-556.
35. Kappos L, CohenJ, Collins W, et al. Fingolimod in relapsing multiple sclerosis: An integratedanalysis of safety findings. Multiple sclerosis and related disorders.2014;3(4):494-504.
36. Kappos L, RadueEW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod inrelapsing multiple sclerosis. The New England journal of medicine.2010;362(5):387-401.
37. Cohen JA,Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon forrelapsing multiple sclerosis. The New England journal of medicine.2010;362(5):402-415.
38. Laroni A, Brogi D, Morra VB, et al. Safetyof the first dose of fingolimod for multiple sclerosis: results of anopen-label clinical trial. BMC neurology. 2014;14:65.
39. Comi G, Kappos L,Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a inrelapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum12-month, phase 3 trial. Lancet neurology. 2019;18(11):1009-1020.
40. Cohen JA, ComiG, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1ain relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24month,phase 3 trial. Lancet neurology. 2019;18(11):1021-1033.
41. Fox RJ, MillerDH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 orglatiramer in multiple sclerosis. The New England journal of medicine.2012;367(12):1087-1097.
42. Gold R, KapposL, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 forrelapsing multiple sclerosis. The New England journal of medicine.2012;367(12):10981107.
43. Scannevin RH,Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervoussystem cells against oxidative stress via the nuclear factor (erythroid-derived2)like 2 pathway. J Pharmacol Exp Ther. 2012;341(1):274-284.
44. Linker RA, LeeDH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects inneuroinflammation via activation of the Nrf2 antioxidant pathway. Brain : ajournal of neurology. 2011;134(Pt 3):678-692.
45. Mills EA, Mao-Draayer Y. Aging andlymphocyte changes by immunomodulatory therapies impact PML risk in multiplesclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England).2018;24(8):1014-1022.
46. Naismith RT, Wundes A, Ziemssen T, et al.Diroximel Fumarate Demonstrates an Improved Gastrointestinal TolerabilityProfile Compared with Dimethyl Fumarate in Patients with Relapsing-RemittingMultiple Sclerosis: Results from the Randomized, Double-Blind, Phase IIIEVOLVE-MS-2 Study. CNS Drugs. 2020;34(2):185-196.
47. O'Connor P,Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide forrelapsing multiple sclerosis. The New England journal of medicine.2011;365(14):12931303.
48. Kieseier BC.The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNSDrugs. 2011;25(6):491-502.
49. Kappos L, KuhleJ, Multanen J, et al. Factors influencing long-term outcomes inrelapsing-remitting multiple sclerosis: PRISMS-15. Journal of neurology,neurosurgery, and psychiatry. 2015;86(11):1202-1207.
50. Interferonbeta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinicalresults of a multicenter, randomized, double-blind, placebo-controlled trial.The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-661.
51. Jacobs LD,Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for diseaseprogression in relapsing multiple sclerosis. The Multiple SclerosisCollaborative Research Group (MSCRG). Annals of neurology. 1996;39(3):285-294.
52. Rudick RA,Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologicdisability in relapsing multiple sclerosis. The Multiple SclerosisCollaborative Research Group (MSCRG). Neurology. 1997;49(2):358-363.
53. PRISMS-4
ong-term efficacy of interferon-beta-1a in relapsing MS. Neurology.2001;56(12):1628-1636.
54. Johnson KP,Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) iswell tolerated and maintains its clinical effect on multiple sclerosis relapserate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.Neurology. 1998;50(3):701-708.
55. Johnson KP,Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improvesdisability in relapsing-remitting multiple sclerosis: results of a phase IIImulticenter, double-blind placebo-controlled trial. The Copolymer 1 MultipleSclerosis Study Group. Neurology. 1995;45(7):1268-1276.
56. Lalive PH,Neuhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiplesclerosis: emerging concepts regarding its mechanism of action. CNS Drugs.2011;25(5):401-414.
57. Cadavid D,Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b orglatiramer acetate by monthly brain MRI in the BECOME study. Neurology.2009;72(23):1976-1983.
58. Goodin DS,Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone)for the treatment of multiple sclerosis: report of the Therapeutics andTechnology Assessment Subcommittee of the American Academy of Neurology. Neurology.2003;61(10):1332-1338.
59. Coles AJ,Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in earlymultiple sclerosis. The New England journal of medicine.2008;359(17):1786-1801.
60. Cohen JA, ColesAJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-linetreatment for patients with relapsing-remitting multiple sclerosis: arandomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828.
61. Coles AJ,Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiplesclerosis after disease-modifying therapy: a randomised controlled phase 3trial. Lancet. 2012;380(9856):1829-1839.
62. Giovannoni G,Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine forrelapsing multiple sclerosis. The New England journal of medicine.2010;362(5):416-426.
63. Cohen JA,Baldassari LE, Atkins HL, et al. Autologous Hematopoietic Cell Transplantationfor Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement fromthe American Society for Blood and Marrow Transplantation. Biology of blood andmarrow transplantation : journal of the American Society for Blood and MarrowTransplantation. 2019;25(5):845-854.
64. Kappos L,Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressivemultiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet.2018;391(10127):1263-1273.
65. Thompson AJ, Banwell BL, Barkhof F, et al.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet neurology. 2018;17(2):162-173.
66. Lassmann H.Pathogenic Mechanisms Associated With Different Clinical Courses of MultipleSclerosis. Front Immunol. 2018;9:3116. 67. Frischer JM, Bramow S, Dal-Bianco A,et al. The relation between inflammation and neurodegeneration in multiplesclerosis brains. Brain : a journal of neurology. 2009;132(Pt 5):1175-1189.
68. Haider L,Zrzavy T, Hametner S, et al. The topograpy of demyelination andneurodegeneration in the multiple sclerosis brain. Brain : a journal ofneurology. 2016;139(Pt 3):807-815.
69. Randomiseddouble-blind placebo-controlled study of interferon beta-1a inrelapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses andDisability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) StudyGroup. Lancet. 1998;352(9139):1498-1504.
70. Calabresi PA,Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a forrelapsingremitting multiple sclerosis (ADVANCE): a randomised, phase 3,double-blind study. Lancet neurology. 2014;13(7):657-665.